HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Robert J. Korst Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Merritt, R. E. Articles by Korst, R. J. Search for Related Content PubMed PubMed Citation Articles by Merritt, R. E. Articles by Korst, R. J. Related Collections Lung - cancer

J Thorac Cardiovasc Surg 2003;126:1609-1617
© 2003 The American Association for Thoracic Surgery

General thoracic surgery

Cisplatin augments cytotoxic T-lymphocyte–mediated antitumor immunity in poorly immunogenic murine lung cancer

^a Department of Cardiothoracic Surgery, Weill Medical College of Cornell University, New York, NY, USA
^b Division of Pulmonary and Critical Care Medicine, Department of Medicine,, Weill Medical College of Cornell University, New York, NY, USA
^c Department of Genetic Medicine, Weill Medical College of Cornell University, New York, NY, USA

Received for publication November 7, 2002; accepted for publication March 27, 2003.

^* Address for reprints: Robert J. Korst, MD, Department of Cardiothoracic Surgery, M 404, Weill Medical College of Cornell University, 525 E. 68th St, New York, NY 10021, USA
rjk2002{at}med.cornell.edu

OBJECTIVE: Many tumors are poorly immunogenic and resistant to cytotoxic T-lymphocyte–mediated cell lysis. Because cisplatin has been demonstrated to increase tumor cell Fas receptor expression, we hypothesized that cisplatin will enhance cytotoxic T-lymphocyte tumor cell killing and augment the antitumor effect of an active immunotherapy strategy in a poorly immunogenic murine lung cancer model.

METHODS: Lewis lung carcinoma cells were exposed to cisplatin in vitro, and Fas receptor expression and apoptosis in response to an agonistic anti-Fas antibody were quantified using flow cytometry. Wild-type and Fas ligand–deficient mice bearing Lewis lung carcinoma flank tumors were then treated with intraperitoneal cisplatin as well as an intratumoral injection of an adenovirus gene transfer vector encoding CD40 ligand. End points included tumor size, animal survival, and Fas expression (determined using immunofluorescence). Cytotoxicity assays were performed using splenocytes from adenovirus gene transfer vector encoding CD40 ligand–treated animals as effectors and cisplatin-treated Lewis lung carcinoma cells as targets.

RESULTS: Cisplatin induced heightened expression of Fas receptor on Lewis lung carcinoma cells in vitro and in vivo and enhanced apoptosis in cells exposed to an agonistic anti-Fas antibody. In vivo, the combination of 1 dose of intraperitoneal cisplatin and intratumoral adenovirus gene transfer vector encoding CD40 ligand inhibited tumor growth and prolonged survival compared with adenovirus gene transfer vector encoding CD40 ligand alone, resulting in a higher cure rate. This effect was lost in Fas ligand–deficient mice. Splenocytes from adenovirus gene transfer vector encoding CD40 ligand–treated wild-type mice lysed cisplatin-treated Lewis lung carcinoma cells more efficiently than untreated Lewis lung carcinoma cells, an effect lost in splenocytes from Fas ligand–deficient mice.

CONCLUSION: Cisplatin augments the antitumor effect of a cytotoxic T-lymphocyte–mediated immunotherapy strategy, resulting in a higher cure rate than seen with immunotherapy alone. This effect is associated with the enhanced ability of cytotoxic T lymphocytes to lyse tumor cells that have been exposed to cisplatin through Fas/Fas ligand interactions.